Each MPN has unique clinical features with a unifying theme of somatic acquisition of a mutation in either JAK2 (Janus kinase 2), MPL (thrombopoietin receptor), or CALR (calreticulin) in hematopoietic stem cells. This evidence concerns the gene MPL and myeloproliferative neoplasm.